OnDosis Partners with Diamond Therapeutics on Low-Dose Psilocybin Programs
By Rebeca Varela Lores, Investment Associate
February 3, 2026
OnDosis has entered into an agreement with Diamond Therapeutics to support Diamond’s low-dose psilocybin programs using the OnDosis precision dosing platform, the Dosage Manager.
The collaboration focuses on enabling accurate, controlled, and reproducible dosing in clinical research, with the potential to scale from development into future commercial use. Diamond is currently conducting a Phase 2a clinical study evaluating sub-perceptual doses of psilocybin in patients with generalized anxiety disorder (GAD).
As interest in novel mental health therapies grows, this agreement underscores the increasing importance of precision dosing and delivery technologies; especially when working with compounds where dose, frequency, and control are central to both safety and therapeutic potential.
Read the full press release here